Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Semaglutide B · 2 trials · 3 indications
Measured in hours\*nanomoles per liter (h\*nmol/L).
Measured in nanomoles per liter (nmol/L).
Measured in h\*nmol/L
Measured in nmol/L
| Arm | Type | Description |
|---|---|---|
| Sequence A | EXPERIMENTAL | Participants will be administered a single subcutaneous (s.c.) dose of 0.5 mg semaglutide B (1.34 mg/mL) in Period 1 followed by a single s.c. dose of 0.5 mg semaglutide B (0.68 mg/mL) in Period 2. |
| Sequence B | EXPERIMENTAL | Participants will be administered a single s.c. dose of 0.5 mg semaglutide B (0.68 mg/mL) in Period 1 followed by a single s.c. dose of 0.5 mg semaglutide B (1.34 mg/mL) in Period 2. |
| Semaglutide B, 1.34 mg/mL followed by Semaglutide D, 1.0 mg/mL | EXPERIMENTAL | - |
| Semaglutide D, 1.0 mg/mL followed by Semaglutide B, 1.34 mg/mL | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Semaglutide B, 1.34 mg/mL | DRUG | Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously. |
| Semaglutide B, 0.68 mg/mL | DRUG | Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously. |
| Semaglutide D, 1.0 mg/mL | DRUG | Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously. |
Inclusion Criteria: * Male or female * Aged 18-55 years (both inclusive) at the time of signing informed consent * Body mass index (BMI) between 20.0 and 29.9 kilograms per meter square (kg/m\^2) (both inclusive) Exclusion Criteria: * Female who is pregnant, breast-feeding or intends to become pr...
Semaglutide B is an investigational small molecule developed by Novo Nordisk A/S for type 2 diabetes mellitus. It is a GLP1R agonist and has been studied in Phase 1 clinical trials. It is not described as an approved product and remains in clinical development.
Semaglutide B targets GLP1R, the glucagon-like peptide-1 receptor, and acts as an agonist at that receptor. GLP1R agonism is the mechanism described for this asset, which is being developed in the metabolic therapeutic area for type 2 diabetes mellitus.
Semaglutide B is developed by Novo Nordisk A/S, which trades under the ticker NVO. Novo Nordisk is the sponsor behind the Phase 1 trials of this small molecule GLP1R agonist for type 2 diabetes mellitus.
Semaglutide B is in Phase 1 clinical development. Two Phase 1 trials have been completed, and no trials are currently active. The program is investigational and has not been described as approved for any indication.
Semaglutide B has been studied in two completed Phase 1 trials: NCT05689099, which compared two concentrations of semaglutide for the 0.5 mg dose in the United States, and NCT05232708, which compared two different forms of semaglutide in the United Kingdom. Together they enrolled 38 participants.